Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Analysis and Forecast

Posted by ramtbrc on May 18th, 2021

The Vascular Endothelial Growth Factor (VEGF) Inhibitor  Global Market Report 2020-30 by The Business Research Company describes and explains the global vascular endothelial growth factor (VEGF) inhibitor  market and covers 2015 to 2020, termed the historic period, and 2020 to 2025, termed the forecast period, along with further forecasts for the period 2025-2030. The report evaluates the market across each region and for the major economies within each region.

The Vascular Endothelial Growth Factor (VEGF) Inhibitor  Global Market Opportunities And Strategies Report covers vascular endothelial growth factor (VEGF) inhibitor  market drivers, vascular endothelial growth factor (VEGF) inhibitor  market trends, vascular endothelial growth factor (VEGF) inhibitor  market segments, vascular endothelial growth factor (VEGF) inhibitor  market growth rate, vascular endothelial growth factor (VEGF) inhibitor  market major players, and vascular endothelial growth factor (VEGF) inhibitor  market size.

View Complete Report:

https://www.thebusinessresearchcompany.com/report/vascular-endothelial-growth-factor-inhibitor-market

The vascular endothelial growth factor (VEGF) inhibitor  market report focuses particularly on identifying the trends, opportunities, and strategies that can lead to success. O&S reports are available off the shelf and can be delivered to clients on the day of purchase.

Vascular Endothelial Growth Factor (VEGF) Inhibitor  Global Market Opportunities And Strategies Report is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies. The chapter on the impact of COVID-19 gives valuable insights on supply chain disruptions, logistical challenges, and other economic implications of the virus on the market. The chapter also covers markets which have been positively affected by the pandemic.

Request For The Sample Now:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3949&type=smp

Trends in the market include:

Use Of Combination Therapy –

Companies in the vascular endothelial growth factor (VEGF) inhibitor market are focusing on combination therapy which reduces the likelihood of development in resistant cancer cells. Combination therapy uses different drugs with different effects, so that each drug can be used at its optimal dose, without intolerable side effects. Combination drug therapies are also useful for patients with advanced cancers that are not suitable for radiation therapy or surgical treatment.   For instance, in November 2020, Switzerland-based pharmaceutical company, F. Hoffmann-La Roche AG announced that the European Commission (EC) had approved Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

Furthering Innovation Through Collaboration –

Companies in the vascular endothelial growth factor (VEGF) inhibitor market are increasing their product innovation through strategic collaborations. To sustain their position in an increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with each other, as well as with academic and research institutions in this market by way of partnerships, in or out of licensing deals, this trend has been increasing in recent years. For instance, in April 2018, Switzerland based biopharmaceutical company, Molecular Partners collaborated with UK based pharmaceutical AstraZeneca, for the trial of its oncology candidate MP0250 with AstraZeneca’s antineoplastic agent osimertinib (Tagrisso) in Phase Ib/II studies. MP0250 prevents tumor growth by inhibiting two growth factors, hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF). In June 2020, Roche launched Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

The market report is segmented:

By Drug Type -

   a) Eylea

  b) Avastin

   c) Tagrisso

   d) Tecentriq

   e) Others

By Route of Administration -

   a) Intravenous

   b) Intravitreal

   c) Oral

By Application -

   a) Oncology

  b) Ophthalmology

About The Business Research Company: 
The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology. TBRC excels in company, market, and consumer research.

Contact Information: 
The Business Research Company 
Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Like it? Share it!


ramtbrc

About the Author

ramtbrc
Joined: July 1st, 2020
Articles Posted: 825

More by this author